Melphalan/TBI is not more carcinogeneic than cyclophosphamide/TBI for transplant conditioning: Follow-up of 725 patients from a single centre over a period of 26 years

Bone Marrow Transplantation

Volumn 25, Issue 4, 2000, Pages 365-370

  Kulkarni, S ^a   Powles, R ^a   Treleaven, J ^a   Singhal, S ^a,b   Horton, C ^a   Sirohi, B ^a   Bhagawati, N ^a   Tait, D ^a   Saso, R ^a   Killick, S ^a   Pinkerton, R ^a   Atra, A ^a   Meller, S ^a   Mehta, J ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b South Carolina Cancer Center   (United States)

Author keywords

Allogeneic bone marrow transplantation; Conditioning therapy; Second malignant neoplasms

Indexed keywords

CHLORMETHINE DERIVATIVE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; MELPHALAN;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER INCIDENCE; CANCER RISK; CHILD; DRUG CARCINOGENICITY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTIVARIATE ANALYSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SKULL IRRADIATION; WHOLE BODY RADIATION;

EID: 0034001605     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702148     Document Type: Article

References (25)

1. Lowsky R, Lipton J, Fyles G et al. Secondary malignancies after hone marrow transplantation in adults. J Clin Oncol 1994; 12: 2187-2192.
2. Kolb HJ, Guenther W, Duell T et al. Cancer after bone marrow transplantation. JBMTR and EBMT/EULEP Study Group on Late Effects. Bone Marrow Transplant 1992; 10 (Suppl. 1): 135-138.
3. Bhatia S, Ramsay NK, Steinbuch M et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87: 3633-3639.
4. Witherspoon RP, Deeg HJ, Storb R et al. Secondary malignancies after marrow transplantation for leukemia or aplastic anemia. Transplantation 1994; 57: 1413-1418.
5. Traweek ST, Slovak ML, Nademanee AP et al. Myelodysplasia and acute myeloid leukemia occurring after autologous bone marrow transplantation for lymphoma. Leuk Lymphoma 1996; 20: 365-372.
6. Curtis RE, Rowlings PA, Deeg HJ et al. Solid cancers after bone marrow transplantation. New Engl J Med 1997; 336: 897-904.
7. Powles RL, Smith CL, Tiley C et al. The anti-leukaemic action of melphalan and total body irradiation in bone marrow transplantation. Haematol Rev 1990; 4: 23-26.
8. Greene MH, Harris EL, Gershenson DM et al. Melphalan may be more potent leukemogen than cyclophosphamide. Ann Intern Med 1996; 105: 360-367.
9. Cuzick J, Erskine S, Edelman D, Galton DA. Comparison of incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. Br J Cancer 1987; 55: 523-529.
10. Chou RH, Wong GB, Kramer JH et al. Leukaemia following chemotherapy for breast cancer. Cancer Res 1990; 50: 2741-2746.
11. Powles R, Milan S, Horton C et al. A prospective haematooncology patient database: structure and description. Bone Marrow Transplant 1996; 17 (Suppl. 1): S140.
12. Helenglass G, Powles RL, McElwain TJ et al. Melphalan and total body irradiation (TBI) versus cyclophosphamide and TBI as conditioning for allogeneic matched sibling bone marrow transplants for acute myeloblastic leukaemia in first remission. Bone Marrow Transplant 1988; 3: 21-31.
13. Mehta J, Powles R, Treleaven J et al. Long term follow-up of patients undergoing allogeneic hone marrow transplantation for acute myeloid leukaemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine. Bone Marrow Transplant 1996; 18: 741-746.
14. Hjiyannakis P, Mehta J, Milan S et al. Melphalan, single-fraction total-body irradiation and allogeneic bone marrow transplantation for acute leukaemia: review of transplant related mortality. Leak Lymphoma 1997; 25: 565-572.
15. Powles R, Singhal S, Treleaven J et al. Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukaemia on the basis of lymphocyte recovery early after transplantation. Blood 1998; 91: 3481-3486.
16. Parkin DM, Whelan SL, Ferlay J et al. (eds). Cancer Incidence in Five Continents, vol. 7. International Agency for Research on Cancer: Lyon, France (IARC scientific publication No. 143).
17. Kaplan EL, Meier PJ. Non parametric estimation from incomplete observations. Am Stat Assoc 1958; 53: 457-481.
18. Cox DR. Regression models and life tables. J Roy Stat Soc 1972; 34B: 187-220.
19. Swift PS, Cowan MJ, Wara WM et al. Toxicities of total body irradiation for pediatric bone marrow transplantation. Int J Radiat Oncol Biol Phys 1996; 34: 843-851.
20. Kolb HJ, Poetscher C. Late effects after allogeneic bone marrow transplantation. Curr Opin Hematol 1997; 4: 401-407.
21. Yoshimoto Y. Cancer risk among children of atomic bomb survivors. A review of RERF epidemiologic studies. Radiation Effects Research Foundation. JAMA 1990; 264: 596-600.
22. Shimizu Y, Schull WJ, Kato H. Cancer risk among atomic bomb survivors. The RERF Life Span Study. Radiation Effects Research Foundation. JAMA 1990; 264: 601-604.
23. Pierce DA, Shimizu Y, Preston DL et al. Studies of the mortality of atomic bomb survivors. Report 12, Part I. Cancer: 1950-1990. Radiat Res 1996; 146: 1-27.
24. Levine EG, Bloomfield CD. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol 1992; 19: 47-84.
25. Saso R, Kulkarni S, Powles R et al. Secondary MDS/AML in patients treated for myeloma. Blood 1998; 92 (Suppl. 1): 455a.